Aqur Biosciences Reinvents Its Look — and the Future of Cholesterol Care

Aqur Biosciences, Inc. (“Aqur” or the “Company”), a bioscience company dedicated to pioneering next-generation cardiovascular therapies, is proud to announce the launch of its new brand identity — a reflection of the Company’s renewed strategic focus, innovative pipeline, and unwavering commitment to transforming patient care.

The rebrand includes a refreshed logo, a redesigned website, and an updated visual identity that aligns with the Company’s mission to deliver scientifically driven, patient-centric solutions to combat cardiovascular disease.

At the heart of this transformation is the Company’s lead therapeutic candidate, currently in development, targeting high cholesterol with a novel and differentiated PCSK9i mechanism of action. Designed for oral administration, the therapy aims to offer improved patient compliance, broader accessibility, affordable cost, and minimized side effects commonly associated with existing treatments.

“This rebranding marks a pivotal moment in our journey,” said Dr. Michael Fole, MD, Chief Executive Officer of Aqur. “As we advance our cholesterol-lowering therapy into the next phase of development, our new identity reflects the innovation, ambition, and scientific rigor driving us forward.”

The newly launched website, www.aqurbiosciences.com, offers an updated look at the Company’s research pipeline, leadership, and vision—highlighting a world-class team of groundbreaking researchers, visionary inventors, leading physicians, accomplished scientists, and seasoned pharmaceutical industry advisors. The Company has also established strategic collaborations with leading laboratories, top global providers of clinical research services, and experts in commercial insights and healthcare intelligence. These partnerships extend to renowned academic institutions in the United States and throughout the world, as well as innovators in artificial intelligence and molecular modeling.

About Aqur Biosciences, Inc.:

Headquartered in Westlake Village, California, Aqur Biosciences, Inc. is dedicated to revolutionizing high cholesterol treatment. Aqur is advancing AQR-008, an innovative oral PCSK9 inhibitor, with the potential to substantially reduce LDL cholesterol and mitigate the risk of cardiovascular diseases such as heart attack and stroke.

Forward-Looking Statements

This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “intend,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law. Aqur assumes no obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250506639432/en/

This rebranding marks a pivotal moment in our journey.